SAR408701
Total Payments
$103,141
Transactions
15
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $101,185 | 14 | 1 |
| 2018 | $1,956 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $99,418 | 13 | 96.4% |
| Consulting Fee | $3,723 | 2 | 3.6% |
Payments by Type
Research
$99,418
13 transactions
General
$3,723
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Tol Esc Dose IV Single Dose every 2w | SANOFI US SERVICES INC. | $99,418 | 0 |
Top Doctors Receiving Payments for SAR408701
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hackensack, NJ | $99,418 | 13 |
| , M.D., PHD | Medical Oncology | Houston, TX | $1,956 | 1 |
| , M.D | Medical Oncology | Baltimore, MD | $1,767 | 1 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $99,418
- SANOFI-AVENTIS U.S. LLC $3,723
Product Information
- Type Drug
- Total Payments $103,141
- Total Doctors 2
- Transactions 15
About SAR408701
SAR408701 is a drug associated with $103,141 in payments to 2 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2018 to 2019. In 2019, $101,185 was paid across 14 transactions to 1 doctors.
The most common payment nature for SAR408701 is "Unspecified" ($99,418, 96.4% of total).
SAR408701 is associated with 1 research study, including "Tol Esc Dose IV Single Dose every 2w" ($99,418).